EGFR and colorectal carcinoma: Two monoclonal antibodies targeting EGFR, cetuximab and panitumumab, have been shown to be effective in combination with chemotherapy or as monotherapy, with cetuximab-sensitive CRC cells displaying enhanced EGFR internalization, stronger cell growth inhibition, and more enhanced apoptotic signaling [72,73].